Table II.
Dose-response of argatroban.
| aPTT (sec) | INR | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| aPTT (sec) | INR | |||||||||
| Patient | Cirrhosis | Hepatic dysfunction | Prior to argatroban therapy | Following argatroban therapy | Mean value during therapy | Prior to argatroban therapy | Following argatroban therapy | Starting dose (µg/kg/min) | Mean dose (µg/kg/min) | Duration of therapy (days) |
| 1 | − | − | 32.6 | 58.7 | 65.7 | 1.17 | 1.31 | 2 | 1.19 | 18 |
| 2 | − | − | 26.7 | 63.2 | 61.8 | 0.99 | 1.55 | 2 | 2 | 12 |
| 3 | − | − | 24.5 | 68.3 | 60.0 | 1.26 | 1.61 | 2 | 1.52 | 12 |
| 4 | + | + | 40.5 | 84.7 | 68.1 | 1.39 | 2.32 | 0.50 | 0.41 | 9 |
| 5 | − | − | 32.6 | 92.1 | 64.0 | 1.07 | 1.76 | 2 | 1.33 | 14 |
| 6 | − | − | 43.3 | 71.1 | 72.0 | 1.21 | 1.55 | 2 | 1.05 | 16 |
| 7 | − | − | 34.9 | 66.5 | 69.9 | 1.15 | 1.66 | 2 | 2 | 8 |
| 8 | − | − | 28.2 | 66.1 | 67.3 | 1.28 | 1.64 | 2 | 1.61 | 14 |
| 9 | − | − | 41.4 | 67.8 | 73.6 | 1.18 | 1.63 | 2 | 2 | 12 |
| 10 | + | − | 44.2 | 76.4 | 72.2 | 1.48 | 1.82 | 2 | 1.13 | 7 |
| 11 | − | − | 36.4 | 79.1 | 75.8 | 1.28 | 2.49 | 2 | 1.54 | 10 |
| 12 | + | + | 42.1 | 59.4 | 68.4 | 1.31 | 1.5 | 0.50 | 0.45 | 6 |
| 13 | − | − | 39.9 | 62.4 | 77.9 | 0.98 | 1.58 | 2 | 1.53 | 15 |
| 14 | − | − | 45.3 | 68.3 | 74.4 | 1.08 | 1.48 | 2 | 2 | 7 |
| 15 | − | − | 41 | 76.9 | 74.8 | 1.42 | 1.52 | 2 | 1.21 | 7 |
| 16 | + | − | 39 | 76.2 | 78.9 | 1.22 | 2.57 | 2 | 1.58 | 13 |
| 17 | + | − | 45.4 | 78.7 | 74.7 | 1.08 | 1.48 | 2 | 1.41 | 18 |
| 18 | + | − | 39.8 | 77.1 | 70.5 | 1.32 | 1.78 | 2 | 2 | 12 |
| Total | 6+/12- | 2+/16- | 37.7±6.4 | 71.8±9.0 | 70.6±5.4 | 1.22±0.14 | 1.74±0.36 | 1.83±0.49 | 1.44±0.49 | 11.8±3.6 |
aPTT, activated partial thromboplastin time; INR, international normalized ratio.